- Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
AdvisorShares Psychedelics ETF(PSIL)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PSIL
11/20/2026: PSIL (1-star) is currently NOT-A-BUY. Pass it for now.
The AdvisorShares Psychedelics ETF (PSIL) provides actively managed exposure to global companies leading the legal development of psychedelic medicines and therapeutics for mental health. Its primary strengths lie in its dedicated thematic focus, active management flexibility, and daily transparency, offering a turnkey vehicle for a hard-to-access sector. It serves best as a satellite growth allocation for high-risk portfolios seeking exposure to medical innovation. Key risks include high volatility, micro-cap concentration, clinical trial uncertainties, and a relatively high 1.00% expense ratio. Investors should closely monitor regulatory progress, clinical milestones, and broader sentiment toward speculative biotech assets.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Suits investors seeking high-growth potential driven by disruptive medical science and emerging pharmaceutical markets. |
| Momentum investor | Strong fit while signal remains positive | Can capture sharp upward momentum phases during positive clinical trial or regulatory headline cycles. |
| Value investor | Weak fit | The fund holds pre-revenue or early-stage clinical companies that lack traditional value metrics. |
| Dividend/Income investor | Weak fit | The underlying holdings do not pay regular dividends, focusing instead on clinical research and corporate expansion. |
| Low-risk investor | Weak fit | High volatility, micro-cap exposure, and binary clinical trial outcomes expose investors to severe downside risk. |
Investor Profile
Ideal Investor Profile
Risk-tolerant growth investors seeking speculative thematic exposure to the future of mental health therapeutics and psychedelic drug development.
Suitability
Best suited for tactical growth allocations rather than core long-term portfolio holdings or passive index strategies.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | The fund's focus on micro- and small-cap clinical biotech stocks drives sharp price swings. |
| Market risk | High | Adverse macro conditions or shifts in risk-on sentiment can heavily impact speculative equities. |
| Concentration | High | Portfolios are tightly concentrated within a single emerging industry and a limited number of holdings. |
| Tracking/expense | Medium / high | An expense ratio of 1.00% creates a notable hurdle for long-term compounding performance. |
| Liquidity | High | Lower AUM and thinly traded underlying components can result in wider trading spreads. |
| Business/sector quality | High | Many portfolio companies are pre-revenue entities reliant on successful drug approvals and external financing. |
Sector & Industry Intelligence
This fund is not assigned to one sector.
Risk Analysis
Volatility
PSIL exhibits very high historical volatility driven by speculative small-cap biotechnology assets and shifting regulatory frameworks.
Market Risk
Underlying assets face high binary clinical trial risk, cash-burn pressures, and sensitivity to broader macroeconomic liquidity cycles.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Industry | Biotechnology & Pharmaceutical Therapeutics (e.g., Compass Pathways, Atai Life Sciences) | 85 | Provides targeted equity exposure to clinical-stage companies developing psychedelic-based treatments for mental health conditions. |
| Sector | Global Healthcare and Life Sciences | 15 | Adds foundational life sciences exposure and broader medical sector diversification to cushion thematic volatility. |
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type ETF | Historic Profit 21.95% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | ETF Returns Performance |

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

